VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that in connection with its previously announced reverse stock split the Company has been assigned a new stock symbol. The Company's shares were previously quoted on the OTC Bulletin Board under the stock symbol VQPH and will now be reported on the OTC Bulletin Board under the new stock symbol VOQP.

The new stock symbol and the previously reported 1 for 10 reverse stock split will be effected for trading purposes at the beginning of trading on April 30, 2008.

About VioQuest Pharmaceuticals

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the

successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest’s oncology portfolio includes: Xyfid™ (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta™ (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B.

Further information about VioQuest can be found at www.vioquestpharm.com.

« Back to the Massage Creams Resource Center »